Technical Analysis for JANX - Janux Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Multiple of Ten Bearish | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Inside Day | Range Contraction | -1.62% | |
Wide Bands | Range Expansion | -1.62% | |
Wide Bands | Range Expansion | 2.75% | |
MACD Bearish Signal Line Cross | Bearish | -2.78% | |
NR7 | Range Contraction | -2.78% | |
Narrow Range Bar | Range Contraction | -2.78% | |
Multiple of Ten Bearish | Other | -2.78% | |
Wide Bands | Range Expansion | -2.78% |
Alert | Time |
---|---|
10 DMA Resistance | about 14 hours ago |
Up 2% | about 14 hours ago |
60 Minute Opening Range Breakout | about 14 hours ago |
Down 5% | about 15 hours ago |
Down 3% | about 16 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/10/2023
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Tumor Platform Technology Chimeric Antigen Receptor T Cell T Cell Clusters Of Differentiation
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Tumor Platform Technology Chimeric Antigen Receptor T Cell T Cell Clusters Of Differentiation
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 58.6936 |
52 Week Low | 5.65 |
Average Volume | 790,602 |
200-Day Moving Average | 12.78 |
50-Day Moving Average | 19.73 |
20-Day Moving Average | 35.20 |
10-Day Moving Average | 40.05 |
Average True Range | 4.27 |
RSI (14) | 64.41 |
ADX | 47.65 |
+DI | 31.77 |
-DI | 14.83 |
Chandelier Exit (Long, 3 ATRs) | 45.87 |
Chandelier Exit (Short, 3 ATRs) | 21.10 |
Upper Bollinger Bands | 60.95 |
Lower Bollinger Band | 9.45 |
Percent B (%b) | 0.57 |
BandWidth | 146.33 |
MACD Line | 6.36 |
MACD Signal Line | 7.30 |
MACD Histogram | -0.9429 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 43.07 | ||||
Resistance 3 (R3) | 43.09 | 41.70 | 42.36 | ||
Resistance 2 (R2) | 41.70 | 40.61 | 41.69 | 42.12 | |
Resistance 1 (R1) | 40.25 | 39.94 | 39.56 | 40.23 | 41.89 |
Pivot Point | 38.86 | 38.86 | 38.51 | 38.85 | 38.86 |
Support 1 (S1) | 37.41 | 37.77 | 36.72 | 37.39 | 35.73 |
Support 2 (S2) | 36.02 | 37.10 | 36.01 | 35.50 | |
Support 3 (S3) | 34.57 | 36.02 | 35.26 | ||
Support 4 (S4) | 34.55 |